

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 57

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 57

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 57

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

abagovomabum*

abagovomab

immunoglobulin G1, anti-idiotypic anti-[anti-(*Homo sapiens* cancer antigen 125, CA 125, MUC-16) *Mus musculus* monoclonal antibody OC125] *Mus musculus* monoclonal antibody ACA125, clone 3D5 gamma1 heavy chain disulfide with clone 3D5 kappa light chain; (223-223":226-226":228-228") trisulfide dimer

abagovomab

immunoglobuline G1, anti-idiotypic anti-[anti-(*Homo sapiens* cancer antigen 125, CA 125, MUC-16) anticorps monoclonal murin OC125] anticorps monoclonal murin ACA125, chaîne lourde gamma1 du clone 3D5 unie par un pont disulfure à la chaîne légère kappa du clone 3D5; dimère (223-223":226-226":228-228")-trisulfure

abagovomab


inmunoglobulina G1, anti-idiotipo anti-[anti-(*Homo sapiens* cancer antigeno 125, CA 125, MUC-16) anticuerpo monoclonal murino OC125] anticuerpo monoclonal murino ACA125, cadena pesada gamma1 del clon 3D5 unida por un puente disulfuro a la cadena ligera kappa del clon 3D5; dímero (223-223":226-226":228-228")-trisulfuro

Heavy chain/Chaîne lourde/Cadena pesada

QVKLQESGAE	LARPGASVKL	SCKASGYTFT	NYWMQWVKQR	PGQGLDWIGA	50
IYPGDGNTY	THKFKGKATL	TADKSSSTAY	MQLSSLASED	SGVYICARGE	100
GNYAWFAYWG	QGTITVTVSSA	KTTPPSVYPL	APGSAAQTNS	MVTLGCLVKG	150
YFPEPVTVTW	NSGSLSSGVH	TFFAVLQSDL	YTLSSSVTVP	SSTWPSSETVT	200
CNVVHPASST	KVDKIVPRD	CGCKPCICTV	PEVSSVFIFP	PKPKDVLTIIT	250
LTFKVTCTVVV	DISKDDPEVQ	FSEWFDVDEV	HTAQTQPREE	QFNSTFRSVS	300
ELPIMHQDWL	NGKEFKCRVN	SAAFPAIEK	TISKTKGRPK	APQVYTIPPP	350
KEQMAKDKVS	LTCMITDFFP	EDITVEWQWN	GQPAENYKNT	QPMIMTDGYS	400
FVYSKLNQVK	SNWEAGTFT	CSVLHEGLHN	HTEKSLSHS	PGK	443

Light chain/Chaîne légère/Cadena ligera

DIELTQSPAS	LSASVGETVT	ITCQASENIY	SYLAWHQKQ	GKSPQLLVYN	50
AKTLAGGVSS	RFGSGSGTH	FSLKIKSLQP	EDFGIYYCQH	HYGILPTFGG	100
GTKLEIKRAD	AAPTVISFPP	SSEQLTSGGA	SVVCFLNIFY	PKDINVKWKI	150
DGSEKQNGVL	NSWTDQDSKD	STYSMSSTLT	LTKEDEYERHN	SYTCEATHKT	200
STSPIVKSFN	RNEC				214

acidum iodofilticum (¹²³I)iodofiltic acid (¹²³I)(3*R*)-15-[4-¹²³I]iodophenyl]3-methylpentadecanoic acidacide iodofiltique (¹²³I)acide (3*R*)-15-(4-¹²³I]iodophényl)-3-méthylpentadécanoïqueácido iodofiltico (¹²³I)ácido (3*R*)-15-(4-¹²³I]iodofenil)-3-metilpentadecanoicoC₂₂H₃₅¹²³I₂O₂

aclidinii bromidum


aclidinium bromide

(3*R*)-3-[(hydroxy)di(thiophen-2-yl)acetyloxy]-1-(3-phenoxypropyl)-1λ⁵-azabicyclo[2.2.2]octan-1-ylum bromide

bromure d'aclidinium

bromure de (3*R*)-3-[[hydroxybis(thiophén-2-yl)acétyl]oxy]-1-(3-phénoxypropyl)-1-azoniabicyclo[2.2.2]octane

bromuro de aclidinio

bromuro de (3*R*)-1-(3-fenoxipropil)-3-[(hidroxi)di(tiofen-2-il)acetiloxi]-1λ⁵-azabicyclo[2.2.2]octan-1-ilioC₂₆H₃₀BrNO₄S₂**afimoxifenum**

afimoxifene


4-(1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl)phenol

afimoxifène

4-[1-[4-[2-(diméthylamino)éthoxy]phényl]-2-phénylbut-1-ényl]phénol

afimoxifeno

4-[1-[4-[2-(dimetilamino)etoxi]fenil]-2-fenilbut-1-enil]fenol


C₂₆H₂₉NO₂and Z isomer
et l'isomère Z
y el isómero Z**afiberceptum***

afibercept

des-432-lysine-[human vascular endothelial growth factor receptor 1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion protein with human vascular endothelial growth factor receptor 2-(206-308)-peptide (containing Ig-like C2-type 3 domain fragment) fusion protein with human immunoglobulin G1-(227 C-terminal residues)-peptide (Fc fragment)], (211-211':214-214')-bisdisulfide dimer

afibercept

(211-211':214-214')-bisdisulfure du dimère de la dès-432-lysine-[récepteur 1 humain du facteur de croissance endothélial vasculaire-(103-204)-peptide (contenant le domaine Ig-like C2-type 2) protéine de fusion avec le récepteur 2 humain du facteur de croissance endothélial vasculaire-(206-308)-peptide (contenant un fragment du domaine Ig-like C2-type 3) protéine de fusion avec l'immunoglobuline G1 humaine-(227 résidus C-terminaux)-peptide (fragment Fc)]

afibercept	<p>(211-211':214-214')-bisdisulfuro del dímero de la des-432-lisina-[receptor 1 humano del factor de crecimiento endotelial vascular-(103-204)-péptido (que contiene el dominio Ig-like C2-tipo 2) proteína de fusión con el receptor 2 humano del factor de crecimiento endotelial vascular-(206-308)-péptido (que contiene un fragmento del dominio Ig-like C2-tipo 3) proteína de fusión con la inmunoglobulina G1 humana-(227 restos C-terminales)-péptido (fragmento Fc)]</p> <p>$C_{4318}H_{6788}N_{1164}O_{1304}S_{32}$</p> <p>Monomer / Monomère / Monómero</p> <pre> SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI 50 PDGKRIIWDS RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT 100 IIDVVLSPSH GIELSVGEKL VLNCTARTEL NVGIDFNWEY PSSKHQHKKL 150 VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ GLYTCAASSG LMTKKNSTFV 200 RVHEKDKTHT CPFCPAPELL GGPVFLFPP KPKDTLMISR TFEVTCVVVD 250 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN 300 GKEYKCKVSN KALPAIEKT ISKAKQPRE PQVYTLPPSR DELTKNQVSL 350 TCLVKGFYPS DIAVEWESNG QPENNYKTFP PVLDSGSGFF LYSKLTVDKS 400 RWQQGNVFC SVMHEALHNN YTKSLSLSP G 431 </pre> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>30-79 30'-79' 124-185 124'-185' 211-211' 214-214' 246-306 246'-306' 352-410 352'-410'</p>
aleglitazarum aleglitazar	<p>(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid</p>
aléglitazar	<p>acide (2S)-2-méthoxy-3-[4-[2-(5-méthyl-2-phényl-1,3-oxazol-4-yl)éthoxy]-1-benzothiophén-7-yl]propanoïque</p>
aleglitazar	<p>ácido (2S)-3-[4-[2-(2-fenil-1,3-oxazol-5-metil-4-il)etoxi]-1-benzotiofen-7-il]-2-metoxipropanoico</p> <p>$C_{24}H_{23}NO_5S$</p> 
alferminogenum tadenovecum* alferminogene tadenovec	<p>recombinant human adenovirus 5 (replication-deficient, E1-deleted) containing a human fibroblast growth factor-4 cDNA sequence driven by a cytomegalovirus promoter</p>
alferminogène tadénovec	<p>adénovirus 5 humain recombinant (réplication-déficient, région E1-supprimée) contenant la séquence ADN-copie du facteur 4 de croissance du fibroblaste humain sous contrôle d'un promoteur de cytomégalovirus</p>
alferminogén tadenovec	<p>adenovirus 5 humano recombinante (replicación-deficiente, con delección E1) que contiene la secuencia DNA-copia del factor-4 de crecimiento de fibroblastos humanos controlado por un promotor de citomegalovirus</p>

apilimodum

apilimod


1-[(3-methylphenyl)methylidene]-2-[6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)ethoxy]pyrimidin-4-yl]hydrazine

apilimod

1-(3-méthylbenzylidène)-2-[6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)éthoxy]pyrimidin-4-yl]diazane

apilimod

1-(3-metilbencilideno)-2-[6-(morfolin-4-il)-2-[2-(piridin-2-il)etoxi]=pirimidin-4-il]diazano

 $C_{23}H_{26}N_6O_2$ **apricitabinum**


apricitabine

4-amino-1-[(2*R*,4*R*)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2(1*H*)-one

apricitabine

(-)-4-amino-1-[(2*R*,4*R*)-2-(hydroxyméthyl)-1,3-oxathiolan-4-yl]=pyrimidin-2(1*H*)-one

apricitabina

(-)-4-amino-1-[(2*R*,4*R*)-2-(hidroximetil)-1,3-oxatiolan-4-il]pirimidin-2(1*H*)-ona $C_8H_{11}N_3O_3S$ **artemisonum**

artemisone


4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-trimethyldecahydro-12*H*-3,12-epoxyprano[4,3-*j*][1,2]benzodioxepin-10-yl]=thiomorpholine-1,1-dione

artémisone

1,1-dioxyde de 4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-triméthyldécahydro-3,12-époxyprano[4,3-*j*]-1,2-benzodioxépin-10-yl]thiomorpholine

artemisona

1,1-dióxido de 4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-trimetildecáhidro-3,12-epoxipirano[4,3-*j*]-1,2-benzodioxepin-10-il]=tiomorfolina

C₁₉H₃₁NO₆S

ataceptum*
atacept

[86-serine,101-glutamic acid,196-serine,197-serine,222-aspartic acid,224-leucine][human tumor necrosis factor receptor superfamily member 13B-(30-110)-peptide (TAC1 fragment containing TNFR-Cys 1 and TNFR-Cys 2) fusion protein with human immunoglobulin G1-(232 C-terminal residues)-peptide (γ1-chain Fc fragment), (92-92':95-95')-bisdisulfide dimer

atacept

(92-92':95-95')-bisdisulfure du dimère de la [86-sérine,101-acide glutamique,196-sérine,197-sérine,222-acide aspartique,224-leucine]-protéine de fusion du membre 13B humain de la superfamille des récepteurs du facteur de nécrose tumorale-(30-110)-peptide (portion du TAC1 incluant les deux régions riches en cystéine) avec l'immunoglobuline G1 humaine-(232 résidus C-terminaux)-peptide (fragment Fc de la chaîne γ1)

atacept

92-92':95-95')-bisdisulfuro del dímero de la [86-serina,101-ácido glutámico,196-serina,197-serina,222-ácido aspártico,224-leucina]-proteína de fusión del miembro 13B humano de la superfamilia de receptores del factor de necrosis tumoral-(30-110)-péptido (porción del TAC1 que incluye las dos regiones ricas en cisteína) con la inmunoglobulina G1 humana-(232 restos C-terminales)-péptido (fragmento Fc de la cadena γ1)

C₃₁₀₄H₄₇₈₈N₈₅₆O₉₅₀S₄₄

Monomer / Monomère / Monómero				
AMRSCPEEQY	WDPLLGTCMS	CKTICNHQSQ	RTCAAFCRSL	SCRKEQGKFY 50
DHLLRDCISC	ASICGQHPKQ	CAYFCENKLR	SEPKSSDKTH	TCPPCPAPEA 100
EGAPSVFLFP	PKPKDTLMIS	RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV 150
HNAKTKPREE	QYNSTYRVVS	VLTVLHQDWL	NGKEYKCKVS	NKALPSSIEK 200
TISKAKGQPR	EPQVYTLPPS	RDELTKNQVS	LTCLVKGFYP	SDIAVEWESN 250
GQFENNYKTI	PFVLDSDGSF	FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN 300
HYTQKSLSL	PGK			313

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
5-18 5'-18' 21-33 21'-33' 25-37 25'-37' 42-57 42'-57' 60-71
60'-71' 64-75 64'-75' 92-92' 95-95' 127-187 127'-187' 233-291 233'-291'

azilsartanum
azilsartan



2-ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid

azilsartan

acide 2-éthoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-biphényl-4-yl]méthyl]-1H-benzimidazole-7-carboxylique

azilsartán

ácido 2-etoxi-1-[[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1H-bencimidazol-7-carboxílico



bavituximabum*
bavituximab


immunoglobulin G1, anti-(phosphatidylserine) chimeric monoclonal ch3G4; gamma1 heavy chain (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfide with kappa light chain (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC); (229-229":232-232")-bisdisulfide dimer

bavituximab

immunoglobuline G1, anti-(phosphatidylsérine) anticorps monoclonal chimérique ch3G4; chaîne lourde gamma1 (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfure avec la chaîne légère kappa (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC); dimère (229-229":232-232")-bisdisulfure

bavituximab

inmunoglobulina G1, anti-(fosfatidilserina) anticuerpo monoclonal quimérico ch3G4; cadena pesada gamma1 (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfuro con la cadena ligera kappa (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC), dímero (229-229":232-232")-bisdisulfuro



Heavy chain / Chaîne lourde / Cadena pesada

EVQLQQSGPE	LEKPGASVKL	SCKASGYSFT	GYNMNVKQS	HGKSLWEIGH	50
IDPYYGDTSY	NQKFRGKATL	TVDKSSSTAY	MQLKSLTSED	SAVYYCVKGG	100
YYGHWYFDVW	GAGTTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSKV	HTFPAPLQSS	GLYSLSVVT	VPSSSLGTQT	200
YICNVNHKFS	NTKVDKVEP	KSCDKHTCP	PCPAPPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTQVVDVVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSRDE	LTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPPV	400
LDSGDSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK	450

k Chain / Chaîne k / Cadena k

DIQMTQSPSS	LSASLGERVS	LTCRASQDIG	SSLNWLQQGP	DGTIKRLIYA	50
TSSLDGVPK	RFSGSRSGSD	YSLTISSLES	EDFVDYYCLQ	YVSSPPTFGA	100
GTKLELKRAD	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22"-96" 23-88" 23"-88" 134-194' 134"-194'" 147-203 147"-203"
214'-223 214"-223" 229-229" 232-232" 264-324 264'-324'" 370-428 370"-428"

bedoradrinum

bedoradrine


2-[[[(7S)-7-((2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide

bédoradrine

(-)-2-[[[(7S)-7-[[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyéthyl)phényl]éthyl]amino]-5,6,7,8-tétrahydronaphtalén-2-yl]oxy]-N,N-diméthylacétamide

bedoradrina

(-)-2-[[[(7S)-7-((2R)-2-hidroxi-2-[4-hidroxi-3-(2-hidroxietil)fenil]etil)amino]-5,6,7,8-tetrahidronaftalen-2-il]oksi]-N,N-dimetilacetamida

C₂₄H₃₂N₂O₅**bepermingenum perplasmidum***

bepermingene perplasmid

plasmid DNA containing human hepatocyte growth factor cDNA sequence driven by a cytomegalovirus promoter

béperringène perplasmide

ADN plasmidique contenant la séquence ADN-copie du facteur de croissance de l'hépatocyte humain sous contrôle d'un promoteur de cytomégalovirus

beperringén perplásmido

DNA de plásmido que contiene la secuencia DNA-copia del factor de crecimiento del hepatocito humano controlado por un promotor de citomegalovirus

beroctocogum alfa*

beroctocog alfa


human blood-coagulation factor VIII-(1-740)-peptide complex with human blood-coagulation factor VIII-(1649-2332)-peptide

béroctocog alfa

combinaison du facteur VIII de coagulation humain-(1-740)-peptide (chaîne lourde du facteur VIIIa, isoforme de 92 kDa) avec le facteur VIII de coagulation humain-(1649-2332)-peptide (chaîne légère du facteur VIIIa)

beroctocog alfa

combinación del factor VIII de coagulación humano-(1-740)-péptido (cadena pesada del factor VIIIa, isoforma de 92 kDa) con el factor VIII de coagulación humano-(1649-2332)-péptido (cadena ligera del factor VIIIa)



Heavy chain / Chaîne lourde / Cadena pesada				
ATRRYYLGAV	ELSWDYMQSD	LGELPVDARF	PPRVKSPFPF	NTSVVYKKTLL 50
FVEFTDHLFN	IAKPRPPWVG	LLGPTIQAEV	YDVTVITLKN	MASHPVSLHA 100
VGVSYWKASE	GAEYDDQTSQ	REKEDDKVFP	GGSHYVYVQV	LKENGPMASD 150
PLCLTYSYLS	HVDLVKDLNS	GLIGALLVCR	EGSLAKEKTQ	TLHKFLLLFA 200
VFDEGKSWHS	ETKNSLMQDR	DAASARAWPK	MHTVNGYVNR	SLPGLIGCHR 250
KSVYWHVIGM	GTTPEVHSIF	LEGHTFLVRN	HRQASLEISF	ITFLTATQTL 300
MDLGQFLLFC	HISSHQHDGM	EAYVKVDSCP	EPPQLRMKNN	EEAEDYDDDL 350
TDSEMDVVRV	DDNSPSFSIQ	IRSVAKKHPK	TWVHYIAAEE	EDWDYAPLVL 400
APDDRSYKSO	YLNNGPQRIG	RKYKKVRFMA	YDDETFPKTRE	AIQHGSLILG 450
PLLYGVEGDT	LLIIFKNQAS	RPYNIYPHGI	TDVVRPLYSR	LPGVKHLLKD 500
FPIILGGEIFK	YKWTYVVEDG	PTKSDPRCLT	RYVSSPVNME	RDLASGLIGP 550
LLICYKESVD	QRGNQIMSDK	RNVILFSVFD	ENRSWYLLEN	IQRFLPNPAG 600
VQLEDPFQFA	SNIMHSINGY	VFDSLQLSVC	LHEVAYWYLL	SIGAQTDFLS 650
VFFSGYTFKH	KMVEDTLTLL	FFFSGETVFM	SMENPGLWLL	GCHNSDFRNR 700
GMTALLKVSS	CDKNTGDYEE	DSYEDISAYL	LSKNNAIEPR	S 741

Light chain / Chaîne légère / Cadena ligera				
TRITLQSDQE	EIDYDDTISV	EMKKEDFDIY	DEDENQSPRS	FQKTRHYFI 1700
AAVERLWDYG	MSSSPHVLRN	RAQSGSVPQF	KKVVFQEFTE	GSFTQPLYRG 1750
ELNEHLGLLG	PYIRAEVEDN	IMVTFRNQAS	RPYSFYSSLI	SYEEDQRQGA 1800
EPRKNFVKFN	ETKTYFWKVQ	HHMAPTKDEF	DKAWAYFSD	VDLEKDVHSG 1850
LIGPLLVCHT	NLTNPAGHRQ	VTVQEFALFF	TIFDETksWY	FTENMERNCR 1900
APCNIQMEDP	TFKENYRFHA	INGYIMDTLP	GLVMAQDQRI	RWYLLSMGSN 1950
ENIHSIHFSG	HVFTVRKKEE	YKMALYNLYP	GVFETVEMLP	SKAGIWRVEC 2000
LIGEHLHAGM	STLFLVYSNK	CQTPLGMSAG	HIRDFQITAS	GQYQWAPKL 2050
ARLHYSGSIN	AWSTKEPFSW	IKVDLLAPMI	IHGKIQGAR	QKFSSLYISQ 2100
FIIIMYSLDGK	KWQTYRGNST	GTLMVFFGNV	DSSGIKHNI	NPPIIARYIR 2150
LHPTHYSIRS	TLRMELMGCD	LNSCSMPLGM	ESKAI SDAQI	TASSYFTNMF 2200
ATWSPSKARL	HLQGRSNAWR	PQVNNPKEWL	QVDFQKTMKV	TGVTQGVKS 2250
LLTSMYVKEF	LISSSQDGHQ	WTLFFQNGKV	KVFQGNQDSF	TPVNSLDPP 2300
LLTRYLRHP	QSWVHQIALR	MEVLGCEAQD	LY	2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 528-554 1899-1903 2021-2169 2174-2326

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn-41 Asn-239 Asn-582 Asn-1810 Asn-2118

Modifications / Modificaciones
Y = 4-O-sulfotyrosyl

bremelanotidum
bremelanotide



2,7-anhydro(*N*-acetyl-L-2-aminohexanoyl-L-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine)

brémelanotide

N-acétyle-L-2-aminohexanoyle-L- α -aspartyle-L-histidyle-D-phénylalanyle-L-arginyle-L-tryptophyle-L-lysine-(2→7)-lactame

bremelanotida

N-acetil-L-2-aminohexanoil-L- α -aspartil-L-histidil-D-fenilalanil-L-arginil-L-triptofil-L-lisina-(2→7)-lactama



bucelipasum alfa*

bucelipase alfa

human bile-salt-activated lipase (cholesterol esterase, EC 3.1.1.13), glycoform alfa (recombinant hBSSL)

bucélipase alfa

lipase activée par les sels biliaires humaine (cholestérol estérase, EC 3.1.1.13), glycoforme alpha (recombinante hBSSL)

bucelipasa alfa

lipasa humana activada por las sales biliares (colesterol esterasa, EC 3.1.1.13), glicofoma alfa (recombinante hBSSL)

C₃₄₃₄H₅₂₅₈N₈₉₄O₁₀₄₁S₁₇

AKLGAVYTEG	GFVEGVNKKL	GLLGDSVDIF	KGIPFAAPTK	ALENPQPHPG	50
WQGTLLKAKNF	KKRCLQATIT	QDSTYGDED	LYLNIWVPOG	RKQVSRDLFV	100
MIWIYGGAPL	MMSGHGANFL	NNYLYDGEEI	ATRGNVIVVT	FNYRVGLPLG	150
LSTGDANLPG	NYGLRDQHMA	IAWVKRNIAA	FGGDPNNITL	FGESAGGASV	200
SLQTLSPYK	GLIRRAISQS	GVALSPWVIQ	KNPLFWAKKV	AEKVGCPVGD	250
AARMAQCCLKV	TDPRALTLAY	KVPLAGLEYV	MLHYVGFVPV	IDGDFIPADP	300
INLYANAADI	DYIAGTNNMD	GHI FAS IDMP	AINKGNKVT	EEDFYKLVSE	350
FTITKGLRGA	KTFDFVYTES	WAQDPSQENK	KKTVVDFETD	VLFVLPTEIA	400
LQHRANAKS	AKTYAYLFSH	PSRMPVYPKW	VGADHADDIQ	YVFGKPFATP	450
TGYRPQDRTV	SKAMLAYWTN	FAKTGDPNMG	DSAVPTHWEV	YTTENSQYLE	500
ITKKMGSSSM	KRSLRTNFLR	YWTLTYLALP	TVTDQEATPV	PPTGDSSEATP	550
VPPTGDSETA	PVPPTGDSGA	PPVPTGDSG	APPVPTGDS	GAPPVPTGD	600
SGAPPVPTG	DSGAPPVPT	GDSGAPPVP	TGDSGAPPV	PTGDAGPPP	650
PPTGDSGAPP	VPTGDSGAP	PVTPTGDS	APVPTGDSG	APPVPTGDS	700
EAAPVPTDD	SKEAQMPAVI	RF			722

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
64-80 246-257

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Asn-187 Thr-538 Thr-549 Thr-559 Thr-576 Thr-587
Thr-598 Thr-609 Thr-620 Thr-631 Thr-642**camobucolum**


camobucol

4-[4-[(2-[[3,5-di(*tert*-butyl)-4-hydroxyphenyl]sulfanyl]propan-2-yl)=sulfanyl]-2,6-di(*tert*-butyl)phenoxy]acetic acid

camobucol

acide 4-[4-[(2-[[3,5-di(*tert*-butyl)-4-hydroxyphényl]sulfanyl]propan-2-yl)sulfanyl]-2,6-di(*tert*-butyl)phénoxy]acétique

camobucol

ácido 4-[4-[(2-[[3,5-di(*terc*-butil)4-hidroxiifenil]sulfanil]propan-2-il)=sulfanil]-2,6-di(*terc*-butil)fenoxi]acéticoC₃₃H₅₀O₄S₂**capadenosonum**

capadenoson


2-amino-6-([2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl)sulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile

capadénoson

2-amino-6-[[[2-(4-chlorophényl)-1,3-thiazol-4-yl]méthyl]sulfanyl]-4-[4-(2-hydroxyéthoxy)phényl]pyridine-3,5-dicarbonitrile

capadenosón

2-amino-6-([2-(4-clorofenil)-1,3-tiazol-4-il]metil)sulfanil]-4-[4-(2-hidroxietoxi)fenil]piridina-3,5-dicarbonitrilo

**catramilastum**



catramilast

1-[(2*S*)-2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]propyl]-1,3-dihydro-2*H*-imidazol-2-one

catramilast

1-[(2*S*)-2-[3-(cyclopropylméthoxy)-4-méthoxyphényl]propyl]-1,3-dihydro-2*H*-imidazol-2-one

catramilast

1-[(2*S*)-2-[3-(ciclopropilmetoxi)-4-metoxifenil]propil]-1,3-dihidro-2*H*-imidazol-2-ona**cediranibum**



cediranib

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

cédiranib

4-[(4-fluoro-2-méthyl-1*H*-indol-5-yl)oxy]-6-méthoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

cediranib

4-[(4-fluoro-2-metil-1*H*-indol-5-il)oxi]-6-metoxi-7-[3-(pirrolidin-1-il)propoxi]quinazolina**denibulinum**

denibulin


methyl [5-[(4-[(2*S*)-2-aminopropanamido]phenyl)sulfanyl]-1*H*-benzimidazol-2-yl]carbamate

dénibuline

[5-[[4-[(2*S*)-2-aminopropanamido]phényl]sulfanyl]-1*H*-benzimidazol-2-yl]carbamate de méthyle

denibulina

[5-[(4-[(2*S*)-2-aminopropanamido]fenil)sulfanil]-1*H*-bencimidazol-2-il]carbamato de metilo

C₁₈H₁₉N₅O₃S**dexelvucitabinum**


dexelvucitabine

4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1*H*)-one

dexelvucitabine

(+)4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1*H*)-one

dexelvucitabina

(+)4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hidroximetil)-2,5-dihidrofuran-2-il]pirimidin-2(1*H*)-onaC₉H₁₀FN₃O₃**efungumabum***

efungumab

immunoglobulin scFv fragment, anti-(heat shock protein 90 homolog from *Candida albicans* (yeast)), methionylalanyl-[human monoclonal HSP90mab VH domain (120 residues)]-tris[(tetraglycyl)seryl]-[human monoclonal HSP90mab V-KAPPA domain (107 residues)]-[arginyl-trialanyl-leucyl-glutamyl]-hexahistidine

éfungumab

immunoglobuline fragment scFv, anti-(homologue de la protéine de choc thermique 90 de *Candida albicans* (levure)), methionylalanyl-[domaine VH (120 résidus) de l'anticorps monoclonal humain HSP90mab]-tris[(tetraglycyl)seryl]-[domaine V-KAPPA (107 résidus) de l'anticorps monoclonal humain HSP90mab]-[arginyl-trialanyl-leucyl-glutamyl]-hexahistidine

efungumab

inmunoglobulina fragmento scFv, anti-(homólogo de la proteína de choc térmico 90 de *Candida albicans*), metionilalanil-[dominio VH (120 restos) del anticuerpo monoclonal humano HSP90mab]-tris[(tetraglicil)seril]-[dominio V-KAPPA (107 restos) del anticuerpo monoclonal humano HSP90mab]-[arginil-trialanil-leucil-glutamil]-hexahistidina

```

MAEVQLVES GAEVKKPGES LRISCKGSGC IISSYWISWV RQMPGKGLEW
MGKIDPGDSY INYSPSFQGH VTISADKSIN TAYLQWNSLK ASDTAMY YCA
RGGDRDFGDSF DYWGQGT LVT VSSGGGGSGG GSGGGGSDV VMTQSPSFLS
AFVGDRTITIT CRASSGISRY LAWYQQAPGK APKLLIYAAS TLQTGVPSRF
SGSGSGTEFT LTINSLQPED FATYQCQLN SYPLTFGGGT KVDIKRAAA
LEhhhhhh

```

elocalcitolum


elocalcitol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-1-fluoro-26,27-dihomo-9,10-secocholesta-5,7,10(19),16,23-pentaene-3,25-diol

élocalcitol

(1*R*,5*S*)-3-[(1*Z*)-2-[(3*aS*,4*E*,7*aS*)-1-[(1*S*,3*E*)-5-éthyl-5-hydroxy-1-méthylhept-3-ényl]-7*a*-méthyl-3,3*a*,5,6,7,7*a*-hexahydro-4*H*-indén-4-ylidène]éthylidène]-5-fluoro-4-méthylidèncyclohexanol

elocalcitol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-1-fluoro-26,27-dihomo-9,10-secocholesta-5,7,10(19),16,23-pentaeno-3,25-diolC₂₉H₄₃FO₂**elsibucolum**


elsibucol

4-{4-[(2-[(3,5-di-*tert*-butyl-4-hydroxyphényl)sulfanyl]propan-2-yl)sulfanyl]-2,6-di-*tert*-butylphénoxy}butanoïque acid

elsibucol

acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]butanoïque

elsibucol

ácido 4-[4-[(2-[(3,5-di-*tert*-butil-4-hidroxfenil]sulfanil)propan-2-il)sulfanil]-2,6-di-*tert*-butilfenoxi]butanoicoC₃₅H₅₄O₄S₂**epoetinum theta**

epoetin theta

human erythropoietin-(1-165)-peptide, glycoform 0

époétine thêta

érythropoïétine humaine-(1-165)-peptide, glycoforme 0

epoetina zeta

eritropoyetina humana-peptido-(1-165), glicoforma 0

C₈₀₉H₁₃₀₁N₂₂₉O₂₄₆S₅

ferroquinum


ferroquine

N'-(7-chloroquinolin-4-yl)-*N,N*-diméthyl-*C,C'*-(ferrocene-1,2-diyl)=diméthanamine

ferroquine

N'-(7-chloroquinoléin-4-yl)-*N,N*-diméthyl-*C,C'*-(férocène-1,2-diyl)=diméthanamine

ferroquina

N'-(7-cloroquinolin-4-il)-*N,N*-dimetil-*C,C'*-(ferroceno-1,2-diil)=dimetanaminaC₂₃H₂₄ClFeN₃**fluticasonum furoas**


fluticasone furoate

6 α ,9-difluoro-17-[[[(fluorométhyl)sulfanyl]carbonyl]-11 β -hydroxy-16 α -méthyl-3-oxoandrosta-1,4-dien-17 α -yl] furan-2-carboxylate

furoate de fluticasone

furane-2-carboxylate de 6 α ,9-difluoro-17-[[[(fluorométhyl)sulfanyl]carbonyl]-11 β -hydroxy-16 α -méthyl-3-oxoandrosta-1,4-dién-17 α -yle

furoato de fluticasona

furano-2-carboxilato de 6 α ,9-difluoro-17-[[[(fluorometil)sulfanil]carbonyl]-11 β -hidroxi-16 α -metil-3-oxoandrosta-1,4-dien-17 α -iloC₂₇H₂₉F₃O₆S**fosalvudinum tidoxilum**

fosalvudine tidoxil


(2*RS*)-2-(decyloxy)-3-[(dodecyl)sulfanyl]propyl [(2*R*,3*S*,5*R*)-3-fluoro-5-(5-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl) tétrahydrofuran-2-yl]méthyle hydrogen phosphate

fosalvudine tidoxil

hydrogénophosphate de (2*RS*)-2-(décyloxy)-3-(dodécylsulfanyl)propyle et de [(2*R*,3*S*,5*R*)-3-fluoro-5-(5-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl) tétrahydrofuran-2-yl]méthyle

fosalvudina tidoxilo

hidrógenofosfato de (2*RS*)-2-(deciloxi)-3-[(dodecil)sulfanil]propilo y [(2*R*,3*S*,5*R*)-3-fluoro-5-(5-metil-2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il)tetrahidrofuran-2-il]metilo

$C_{35}H_{64}FN_2O_8PS$ 

gamithromycinum
gamithromycin


(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl- α -*L*-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -*D*-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one

gamithromycin

(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl- α -*L*-ribo-hexopyranosyl)oxy]-2-éthyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexaméthyl-7-propyl-11-[[3,4,6-tridésoxy-3-(diméthylamino)- β -*D*-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadécan-15-one

gamitromicina

(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil- α -*L*-ribo-hexopiranosil)oxi]-2-etil-3,4,10-trihidroxil-3,5,8,10,12,14-hexametil-7-propil-11-[[3,4,6-tridesoxi-3-(dimetilamino)- β -*D*-xylo-hexopiranosil]oxi]-1-oxa-7-azacilopentadecan-15-ona

 $C_{40}H_{76}N_2O_{12}$ 

ilepatrilum
ilepatril


(4*S*,7*S*,12*bR*)-7-[(2*S*)-2-(acetylsulfanyl)-3-methylbutanamido]-6-oxo-1,2,3,4,6,7,8,12*b*-octahydropyrido[2,1-*a*][2]benzazepine-4-carboxylic acid

ilépatril

acide (4*S*,7*S*,12*bR*)-7-[[2*S*)-2-(acétylsulfanyl)-3-méthylbutanoil]=amino]-6-oxo-1,2,3,4,6,7,8,12*b*-octahydropyrido[2,1-*a*][2]=benzazépine-4-carboxylique

ilepatrilo

ácido (4*S*,7*S*,12*bR*)-7-[[2*S*)-2-(acetilsulfanil)-3-metilbutanoil]amino]-6-oxo-1,2,3,4,6,7,8,12*b*-octahidropirido[2,1-*a*][2]benzazepina-4-carboxílico

C₂₂H₂₈N₂O₅S**imisopasemum manganum**

imisopasem manganese


(PBPY-7-11-2344'3')-dichloro[(4*aR*,13*aR*,17*aR*,21*aR*)-1,2,3,4,4*a*,5,6,12,13,13*a*,14,15,16,17,17*a*,18,19,20,21,21*a*-icosahydro-7,11-(azeno)dibenzo[*b,h*][1,4,7,10]=tetraazacycloheptadecine-κ⁴*N*⁵,*N*¹³,*N*⁸,*N*²¹,*N*²²]manganese

imisopasem manganèse

(PBPY-7-11-2344'3')-dichloro[(4*aR*,13*aR*,17*aR*,21*aR*)-1,2,3,4,4*a*,5,6,12,13,13*a*,14,15,16,17,17*a*,18,19,20,21,21*a*-icosahydro-11,7-nitrilo-7*H*-dibenzo[*b,h*][1,4,7,10]=tétraazacycloheptadécine-κ⁴*N*⁵,κ¹³*N*⁸,κ²¹*N*²²]manganèse

imisopasem manganeso

(PBPY-7-11-2344'3')-dicloro[(4*aR*,13*aR*,17*aR*,21*aR*)-1,2,3,4,4*a*,5,6,12,13,13*a*,14,15,16,17,17*a*,18,19,20,21,21*a*-icosahidro-7,11-(azeno)dibenzo[*b,h*][1,4,7,10]=tetraazacicloheptadecino-κ⁴*N*⁵,*N*¹³,*N*⁸,*N*²¹,*N*²²]manganeso

C₂₁H₃₅Cl₂MnN₅**inakalantum**

inakalant


tert-butyl (2-{7-[(2*S*)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}ethyl)carbamate

inakalant

[2-{7-[(2*S*)-3-(4-cyanophénoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}éthyl]carbamate de 1,1-diméthyléthyle

inakalant

(2-{7-[(2*S*)-3-(4-cianofenoxi)-2-hidroxiopropil]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}etil)carbamato de *tert*-butilo

C₂₃H₃₄N₄O₅

lapaquistatum


lapaquistat

(1-[[[(3*R*,5*S*)-1-(3-hydroxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl)acetic acid

lapaquistat

acide (1-[[[(3*R*,5*S*)-1-(3-hydroxy-2,2-diméthylpropyl)-7-chloro-5-(2,3-diméthoxyphényl)-2-oxo-1,2,3,5-tétrahydro-4,1-benzoxazépin-3-yl]acétyl]pipéridin-4-yl)acétique

lapaquistat

ácido (1-[[[(3*R*,5*S*)-1-[3-hidroxi-2,2-dimetilpropil]-7-cloro-5-(2,3-dimetoxifenil)-2-oxo-1,2,3,5-tetrahidro-4,1-benzoxazepin-3-il]acetil]piperidin-4-il)acéticoC₃₁H₃₉ClN₂O₈**levonadifloxacinum**


levonadifloxacin

(5*S*)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1*H*,5*H*-benzo[*ij*]quinolizine-2-carboxylic acid

lévonadifloxacine

(-)-acide (5*S*)-9-fluoro-8-(4-hydroxypipéridin-1-yl)-5-méthyl-1-oxo-6,7-dihydro-1*H*,5*H*-benzo[*ij*]quinolizine-2-carboxylique

levonadifloxacino

ácido (5*S*)-9-fluoro-8-(4-hidroxipiperidin-1-il)-5-metil-1-oxo-6,7-dihidro-1*H*,5*H*-benzo[*ij*]quinolizina-2-carboxílicoC₁₉H₂₁FN₂O₄**lexatumumabum***

lexatumumab

immunoglobulin G1, anti-[human tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, CD262)] human monoclonal HGS-ETR2; gamma1 heavy chain (*Homo sapiens* VH-IGHG1) (224-213')-disulfide with lambda light chain (*Homo sapiens* V-LAMBDA- IGLC2); (230-230":233-233")-bisdisulfide dimer

lexatumumab immunoglobuline G1, anti-[membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale humain (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticorps monoclonal humain HGS-ETR2; chaîne lourde gamma1 (*Homo sapiens* VH-IGHG1) (224-213')-disulfure avec la chaîne légère lambda (*Homo sapiens* V-LAMBDA- IGLC2); dimère (230-230":233-233")-bisdisulfure

lexatumumab inmunoglobulina G1, anti-[miembro 10B de la superfamilia de receptores del factor de necrosis tumoral humano (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticuerpo monoclonal humano HGS-ETR2; cadena pesada gamma1 (*Homo sapiens* VH-IGHG1) (224-213')-disulfuro con la cadena ligera lambda (*Homo sapiens* V-LAMBDA- IGLC2); dímero (230-230":233-233")-bisdisulfuro

C₆₃₄₆H₉₈₃₂N₁₇₂₀O₂₀₀₂S₄₂

Heavy chain / chaîne lourde / cadena pesada

EVQLVQSGGG	VERPGGSLRL	SCAASGFTFD	DYGMSWVRQA	PGKGLEWVSG	50
INWNGGSTGY	ADSVKGRVTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCAKIL	100
GAGRGWYFDL	WGKGTITVVS	SASTKGPSVF	PLAPSKKSTS	GGTAALGCLV	150
KDYFPEPVTV	SWNSGALTSV	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ	200
TYICNVNHKP	SNTKVDKRVV	PKSCDKTHTC	PCCPAPELLG	GPSVFLFPPK	250
PKDTLMLSRV	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	300
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	350
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTTP	400
VLDSDDGSFFL	YSKLTVDKSR	WQQGNVFCSS	VMHEALHNYH	TQKSLSLSPG	450
K					

Lambda chain / chaîne lambda / cadena lambda

SSELTQDPAV	SVALGQTVRI	TCQGDLSRSY	YASWYQQKPG	QAPVLIYIGK	50
NNRPSGIPDR	FSGSSSGNTA	SLTITGAQAE	DEADYYCNSR	DSSGNHVVFG	100
GGTKLTVLQV	PKAAPSVTLF	PPSSEELQAN	KATLVCLISD	FYPGAVTVAV	150
KADSSPVKAG	VETTTPSKQS	NNKYAASSYL	SLTPEQWKSH	RSYSCQVTHE	200
GSTVEKTVAP	TECS				

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22-87 22-96 22-87 136-195 136-195 148-204 148-204
213-224 213-224 230-230 233-233 265-325 265-325 371-429 371-429"

lifiquatum

lifiquat

[5-(1-benzyl-1*H*-indazol-3-yl)furan-2-yl]methanol


lifiquat

[5-(1-benzyl-1*H*-indazol-3-yl)furan-2-yl]méthanol

lifiquat

[5-(1-bencil-1*H*-indazol-3-il)furan-2-il]metanol

C₁₉H₁₆N₂O₂



lobeglitzonum

lobeglitzone


(5*RS*)-5-[[4-(2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]methylamino]ethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione

lobéglitzone

(5*RS*)-5-4-[2-[[6-(4-méthoxyphénoxy)pyrimidin-4-yl]méthylamino]éthoxy]bencil]thiazolidine-2,4-dione

lobeglitzona

(5*RS*)-5-4-(2-[[6-(4-metoxifenoxi)pirimidin-4-il]metilamino]etoxi)bencil]-1,3-tiazolidina-2,4-diona

$C_{24}H_{24}N_4O_5S$ **lorcaserinum**


lorcaserin

(1*R*)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1*H*-3-benzazépine

lorcasérine

(1*R*)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1*H*-3-benzazépine

lorcaserina

(1*R*)-8-cloro-1-metil-2,3,4,5-tetrahidro-1*H*-3-benzazepina $C_{11}H_{14}ClN$ **mifamurtidum**


mifamurtide

2-[[*N*-[(2*R*)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]=propanoyl]-L-alanyl-D-isoglutaminyl-L-alanyl]amino]ethyl (2*R*)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate

mifamurtide

hydrogénophosphate de 2-[[*N*-[(2*R*)-2-[(3*R*,4*R*,5*S*,6*R*)-3-(acétylamino)-2,5-dihydroxy-6-(hydroxyméthyl)tétrahydro-2*H*-pyran-4-yloxy]propanoyle]-L-alanyl-D-isoglutaminyl-L-alanyl]amino]éthyle et de (2*R*)-2,3-bis(hexanoiloxy)propyle

mifamurtida

hidrógenofosfato de 2-[[*N*-[(2*R*)-2-[(3*R*,4*R*,5*S*,6*R*)-3-(acetilamino)-2,5-dihidroxi-6-(hidroximetil)tetrahidro-2*H*-piran-4-iloxi]propanoile]-L-alanil-D-isoglutaminil-L-alanil]amino]etilo y de (2*R*)-2,3-bis(hexanoiloxi)propilo $C_{59}H_{109}N_6O_{19}P$ **migalastatum**

migalastat



(2*R*,3*S*,4*R*,5*S*)-2-(hydroxyméthyl)piperidine-3,4,5-triol

migalastat

(±)-(2*R*,3*S*,4*R*,5*S*)-2-(hydroxyméthyl)pipéridine-3,4,5-triol

migalastat

(2*R*,3*S*,4*R*,5*S*)-2-(hidroximetil)piperidina-3,4,5-triol

**mirodenafilum**

mirodenafil



5-ethyl-2-(5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl)-7-propyl-3,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

mirodénafil

5-éthyl-2-[5-[[4-(2-hydroxyéthyl)pipérazin-1-yl]sulfonyl]-2-propoxyphényl]-7-propyl-3,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

mirodenafilo

5-etil-2-(5-[[4-(2-hidroxietil)piperazin-1-il]sulfonyl]-2-propoxifenil)-7-propil-3,5-dihidro-4*H*-pirrolo[3,2-*d*]pirimidin-4-ona

**motavizumabum***

motavizumab

immunoglobulin G1, anti-(human respiratory syncytial virus glycoprotein F) humanized monoclonal MEDI-524; gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens* IGHG1] (223-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens* IGKC]; (229-229'':232-232'')-bisdisulfide dimer

motavizumab

immunoglobuline G1, anti-(glycoprotéine de fusion du virus syncytial respiratoire humain) anticorps monoclonal humanisé MEDI-524; chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR)- *Homo sapiens* IGHG1] (223-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens* IGKC]; dimère (229-229'':232-232'')-bisdisulfure

motavizumab

inmunoglobulina G1, anti-(glicoproteína de fusión del virus sincitial respiratorio humano) anticuerpo monoclonal humanizado MEDI-524; cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR)- *Homo sapiens* IGHG1] (223-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR)- *Homo sapiens* IGKC]; (229-229'':232-232'')-bisdisulfide dimer

C₆₄₇₆H₁₀₀₁₄N₁₇₀₆O₂₀₀₈S₄₈

γ-1-Chain / Chaîne γ-1 / Cadena γ-1

QVTLRESGPA	LVKPTQTLTL	TCTFSGFSL	TAGMSVGWIR	QPPGKALEWL	50
ADIWDDKKH	YNPSLKDRLT	ISKDTSKNQV	VLKVTNMDPA	DTATYYCARD	100
MIFNFYFDVW	GQTTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAAALGLVK	150
DYFPEPVTVS	WNSGALTSKV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKRVPE	KSCDKHTHCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTPPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK	450

κ Chain / Chaîne κ / Cadena κ

DIQMTQSPST	LSASVGDRTV	ITCSASSRVG	YMHVYQQKPG	KAPKLLIYDT	50'
SKLASGVPSR	FSGSGSGTEF	TLTISSLQPD	DFATYYCFQG	SGYPFTFGGG	100'
TKVEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150'
NALQSGNSQE	SVTEQDSKDS	TYSLSTLTL	SKADYERKRV	YACEVTHQGL	200'
SSPVTKSFNR	GEC				213'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-97 22'-97" 23-87" 23'-87" 133-193" 133'-193" 147-203 147'-203"
213'-223 213"-223" 229-229" 232-232" 264-324 264"-324" 370-428 370"-428"**naproxcinodum**

naproxcinod


4-(nitrooxy)butyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate

naproxcinod

(2S)-2-(6-méthoxynaphthalén-2-yl)propanoate de 4-(nitrooxy)butyle

naproxcinod

(2S)-2-(6-metoxinaftalen-2-il)propanoato de 4-(nitrooxi)butilo

C₁₈H₂₁NO₆**omriptolidum**

omriptolide


4-[[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-methyl-6a-(propan-2-yl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahydrotrioxireno=[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-6-yl]oxy]-4-oxobutanoic acid

omriptolide

acide 4-[[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-méthyl-6a-(1-méthyléthyl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodécahydrotrioxiréno[4b,5:6,7:8a,9]phénanthro[1,2-c]furan-6-yl]=oxy]-4-oxobutanoïque

omriptolida

ácido 4-[[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-metil-6a-(propan-2-il)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahidrotrioxireno[4b,5:6,7:8a,9]fenantro[1,2-c]furan-6-il]oxi]-4-oxobutanoico

C₂₄H₂₈O₉

pafuramidinum


pafuramidine

4,4'-(furan-2,5-diyl)bis(*N*-methoxybenzenecarboximidamide)

pafuramidine

4,4'-(furane-2,5-diyl)bis(*N*-méthoxybenzèncarboximidamide)

pafuramidina

4,4'-(furano-2,5-diil)bis(*N*-metoxibencenocarboximidamida)C₂₀H₂₀N₄O₃**pramiconazolum**


pramiconazole

1-(4-{4-[4-((2*S*,4*R*)-4-(2,4-difluorophenyl)-4-[(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-2-yl)methoxy]phenyl}piperazin-1-yl)phenyl)-3-(propan-2-yl)imidazolidin-2-one

pramiconazole

(+) -1-[4-[4-[4-[[2*S*,4*R*]-4-(2,4-difluorophényl)-4-[(1*H*-1,2,4-triazol-1-yl)méthyl]-1,3-dioxolan-2-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-3-(1-méthyléthyl)imidazolidin-2-one

pramiconazol

1-(4-{4-[4-((2*S*,4*R*)-4-(2,4-difluorofenil)-4-[(1*H*-1,2,4-triazol-1-il)metil]-1,3-dioxolan-2-il}metoxi)fenil]piperazin-1-il}fenil)-3-(propan-2-il)imidazolidin-2-onaC₃₅H₃₉F₂N₇O₄**prinaberelum**

prinaberel


7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol

prinabérel

7-éthényl-2-(3-fluoro-4-hydroxyphényl)-1,3-benzoxazol-5-ol

prinaberel

7-etenil-2-(3-fluoro-4-hidroxifenil)-1,3-benzoxazol-5-ol

C₁₅H₁₀FNO₃

rilonaceptum*

rilonacept

[653-glycine][human interleukin-1 receptor accessory protein-(1-339)-peptide (extracellular domain fragment) fusion protein with human type 1 interleukin-1 receptor-(5-316)-peptide (extracellular domain fragment) fusion protein with human immunoglobulin G1-(229 C-terminal residues)-peptide (Fc fragment)], (659-659':662-662')-bisdisulfide dimer

rilonacept

(659-659':662-662')-bisdisulfure du dimère de la [653-glycine][protéine accessoire du récepteur de l'interleukine-1 humaine-(1-339)-peptide (fragment du domaine extracellulaire) protéine de fusion avec le récepteur de type I humain de l'interleukine-1-(5-316)-peptide (fragment du domaine extracellulaire) protéine de fusion avec l'immunoglobuline G1 humaine-(229 résidus C-terminaux)-peptide (fragment Fc)]

rilonacept

(659-659':662-662')-bisdisulfuro del dímero de la [653-glicina][proteína accesoria del receptor de la interleukina-1 humana-(1-339)-péptido (fragmento del dominio extracelular) proteína de fusión con el receptor de tipo I humano de la interleukina-1-(5-316)-péptido (fragmento del dominio extracelular) proteína de fusión con la inmunoglobulina G1 humana-(229 restos C-terminales)-péptido (fragmento Fc)]

C₉₀₃₀H₁₃₉₃₂N₂₄₀₀O₂₆₇₀S₇₄

Monomer / Monomère / Monómero

SERCDDWGLD	TMRQIQVFED	EPARIKCPFL	EHFLKFNYS	AHSAGLTLIW	50
YWTRQDRDLE	EPINFRLPEN	RISKEKDVW	FRPTLLNDTG	NYTCMLRNTT	100
YCSKVAFPLE	VVQKDSFNS	PMKLPVHKLY	IEYGIQRITC	PNVDGYFPSS	150
VKPTITWYMG	CYKIQNFNV	IPEGMNSFL	IALISNNGNY	TCVVTYPENG	200
RTFHLTRTLT	VKVVGSPKNA	VPPVIHSPND	HVVYEKEPGE	ELLIPCTVYF	250
SFLMDSRNEV	WWTIDGKKPD	DITIDVTINE	SISHSRTEDE	TRTQILSIK	300
VTSDELKRSY	VCHARSAGE	VAKAAKVKQK	VPAPRYTVEK	CKEREKIIIL	350
VSSANEIDVR	PCPLNPNEHK	GTITWYKDD	KTPVSTEQAS	RIHQHKEKWL	400
FVPAKVEDSG	HYCVVRNNS	YCLRKISAK	FVENEPNLCY	NAQAIFKQKL	450
PVAGDGLVLC	PYMEFFKNEN	NELPKLQWYK	DCPKLLLDNI	HFSGVKDRLI	500
VMNVAEKHRG	NYTCHASYTY	LKGQYPI TRV	IEFITLEENK	PTRPVIVSPA	550
NETMEVDLGS	QIQLICNVITG	QLSDIAYWKW	NGSVIEDDDP	VLGEDYYSVE	600
NPANKRRSTL	ITVLNISEIE	SRFYKHPFTC	FAKNTHGIDA	AYIQLIYFVT	650
NSGDKTHTCP	PCPAPELLGG	PSVFLFPPKP	KDTLMISRTP	EVTCVVVDVS	700
HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	STYRVVSVLT	VLHQDWLNGK	750
EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	VYTLPPSRDE	LTKNQVSLTC	800
LVKGFYPSDI	AVEWESNGQP	ENNYKTPPV	LSDGGSFFLY	SKLTVDKSRW	850
QQGNVFSCSV	MHEALHNYHT	QKSLSLSPGK			880

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

4-102 4'-102' 27-94 27'-94' 117-161 117'-161' 140-192 140'-192' 246-312
246'-312' 341-422 341'-422' 362-414 362'-414' 339-482 339'-482' 460-514 460'-514'
566-630 566'-630' 659-659' 662-662' 694-754 694'-754' 800-858 800'-858'

rosabulinum

rosabulin


2-{3-[(4-cyanophenyl)methyl]indolizin-1-yl}-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide

rosabuline

2-[3-(4-cyanobenzyl)indolizin-1-yl]-N-(3-méthylisothiazol-5-yl)-2-oxoacétamide

rosabulina

2-{3-[(4-cianofenil)metil]indolizin-1-il}-N-(3-metilisotiazol-5-il)-2-oxoacetamida

C₂₂H₁₆N₄O₂S

sagopilonum
sagopilone


(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

sagopilone

(-)-(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,12,16-tétraméthyl-3-(2-méthyl-1,3-benzothiazol-5-yl)-10-(prop-2-ényl)-4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione

sagopilona

(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihidroxi-8,8,12,16-tetrametil-3-(2-metil-1,3-benzotiazol-5-il)-10-(prop-2-enil)-4,17-dioxabicyclo[14.1.0]heptadecano-5,9-diona

C₃₀H₄₁NO₆S

sodelglitazarum
sodelglitazar


2-{4-[[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy}-2-methylpropanoic acid

sodelglitazar

acide 2-[4-[[[2-[2-fluoro-4-(trifluorométhyl)phényl]-4-méthyl-1,3-thiazol-5-yl]méthyl]sulfanyl]-2-méthylphénoxy]-2-méthylpropanoïque

sodelglitazar

ácido 2-[4-[[[2-[2-fluoro-4-(trifluorometil)fenil]-4-metil-1,3-tiazol-5-il]metil]sulfanil]-2-metilfenoxi]-2-metilpropanoico

C₂₃H₂₁F₄NO₃S₂

sofigatranum


sofigatran

propyl {(1*S*)-1-[(2*S*)-2-[(*trans*-4-aminocyclohexylmethyl)carbamoyl]=pyrrolidine-1-carbonyl]-2-methyl-2-[(propan-2-yl)sulfanyl]propyl}=carbamate

sofigatran

[(1*S*)-1-[(2*S*)-2-[(*trans*-4-aminocyclohexyl)méthyl]carbamoyl]=pyrrolidin-1-yl]carbonyl]-2-méthyl-2-[(1-méthyléthyl)sulfanyl]propyl]=carbamate de propyle

sofigatrán

[(1*S*)-1-[(2*S*)-2-[(*trans*-4-aminociclohexil)metil]carbamoil]pyrrolidin-1-il]carbonil]-2-metil-2-[(propan-2-il)sulfaniil]propil]carbamato de propiloC₂₄H₄₄N₄O₄S**succinobucolum**


succinobucol

4-{4-[(2-[(3,5-di(*tert*-butyl)-4-hydroxyphenyl)sulfanyl]propan-2-yl)=sulfanyl]-2,6-di(*tert*-butyl)phenoxy]-4-oxobutanoic acid

succinobucol

acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]-4-oxobutanoïque

succinobucol

ácido 4-[4-[(2-[(3,5-di(*terc*-butil)4-hidroxfenil]sulfaniil)propan-2-il)=sulfaniil]-2,6-di(*terc*-butil)fenoxi]-4-oxobutanoicoC₃₅H₅₂O₅S₂**taribavirinum**

taribavirin



1-β-D-ribofuranosyl-1*H*-1,2,4-triazole-3-carboximidamide

taribavirine

1-β-D-ribofuranosyl-1*H*-1,2,4-triazole-3-carboximidamide

taribavirina

1-β-D-ribofuranosil-1*H*-1,2,4-triazol-3-carboximidamida

**tezampanelum**



tezampanel

(3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid

tézampanel

(-)-acide (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tétrazol-5-yl)éthyl]=
décahydroisoquinoléine-3-carboxylique

tezampanel

(-)-ácido (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tetrazol-5-il)etil]=
decahidroisoquinolina-3-carboxílico**ticagrelorum**



ticagrelor

(1*S*,2*S*,3*R*,5*S*)-3-(7-[[1*R*,2*S*]-2-(3,4-difluorophenyl)cyclopropyl]=
amino)-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl)-
5-(2-hydroxyethoxy)cyclopentane-1,2-diol

ticagrélor

(1*S*,2*S*,3*R*,5*S*)-3-[7-[[1*R*,2*S*]-2-(3,4-difluorophényl)cyclopropyl]=
amino]-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl)-
5-(2-hydroxyéthoxy)cyclopentane-1,2-diol

ticagrelor

(1*S*,2*S*,3*R*,5*S*)-3-(7-[[1*R*,2*S*]-2-(3,4-difluorofenil)ciclopropil]amino)-
5-(propilsulfanil)-3*H*-[1,2,3]triazolo[4,5-*d*]pirimidin-3-il)-
5-(2-hidroxietoxi)ciclopentano-1,2-diol


tigapotidum
tigapotide

L-glutamyl-L-tryptophyl-L-glutaminy-L-threonyl-L-aspartyl-L-asparaginy-L-S-[(acetamido)methyl]-L-cysteinyl-L-glutamyl-L-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-tyrosyl-L-glutamyl-L-threonine

tigapotide

 S^{37} - S^{40} , S^{42} -tris[acétylamino)méthyl]bêta-microséminoprotéine humaine (protéine PSP94 sécrétée par la prostate)-(31-45)-peptide

tigapotida

 S^{37} - S^{40} , S^{42} -tris[acetilamino)metil]beta-microseminoproteína humana (proteína PSP94 secretada por la próstata)-(31-45)-péptido $C_{82}H_{119}N_{21}O_{34}S_3$ **tipelukastum**
tipelukast


4-(6-acetyl-3-{3-[(4-acetyl-3-hydroxy-2-propylphenyl)sulfanyl]=propoxy}-2-propylphenoxy)butanoic acid

tipélukast

acide 4-[6-acétyl-3-[3-[(4-acétyl-3-hydroxy-2-propylphényl)sulfanyl]=propoxy]-2-propylphénoxy]butanoïque

tipelukast

ácido 4-[6-acetil-3-[3-[(4-acetil-3-hidroxi-2-propilfenil)sulfanil]=propoxil]-2-propilfenoxi]butanoico


 $C_{29}H_{38}O_7S$ **tomopenemum**
tomopenem(4*R*,5*S*,6*S*)-3-(((3*S*,5*S*)-5-[(3*S*)-3-(carbamimidamidoacetamido)=pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl)sulfanyl)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

tomopénem

(-)-acide (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[[[(3*S*)-3-[(carbamimidoylamino)=acétylamino]pyrrolidin-1-yl]carbonyl]-1-méthylpyrrolidin-3-yl]=sulfanyl]-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]=hept-2-ène-2-carboxylique

tomopenem

ácido (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[[[(3*S*)-3-(carbamimidamidoacetamido)pirrolidin-1-il]carbonil]-1-metilpirrolidin-3-il]sulfanil]-6-[(1*R*)-1-hidroxietil]-4-metil-7-oxo-1-azabicyclo[3.2.0]=hept-2-eno-2-carboxílico

**tylvalosinum**

tylvalosin



(4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-deoxy-2,3-di-*O*-methyl-β-*D*-allopyranosyl)oxy]methyl]-6-({3,6-dideoxy-4-*O*-[2,6-dideoxy-3-*C*-methyl-4-*O*-(3-methylbutanoyl)-α-*L*-*ribo*-hexopyranosyl]-3-(dimethylamino)-β-*D*-glucopyranosyl)oxy]-16-ethyl-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl] acetate

tylvalosine

(-)-acétate de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-désoxy-2,3-di-*O*-méthyl-β-*D*-allopyranosyl)oxy]méthyl]-6-[[[3,6-didésoxy-4-*O*-[2,6-didésoxy-3-*C*-méthyl-4-*O*-(3-méthylbutanoyl)-α-*L*-*ribo*-hexopyranosyl]-3-(diméthylamino)-β-*D*-glucopyranosyl]oxy]-16-éthyl-5,9,13-triméthyl-2,10-dioxo-7-(2-oxoéthyl)oxacyclohexadéca-11,13-dién-4-yle

tilvalosina

(-)-acetato de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-desoxi-2,3-di-*O*-metil-β-*D*-alopiranosil)oxil]metil]-6-[[[3,6-didesoxi-4-*O*-[2,6-didesoxi-3-*C*-metil-4-*O*-(3-metilbutanoil)-α-*L*-*ribo*-hexopiranosil]-3-(dimetilamino)-β-*D*-glucopiranosil]oxil]-16-etil-5,9,13-trimetil-2,10-dioxo-7-(2-oxoetil)oxaciclohexadeca-11,13-dien-4-ilo

**vabicaserinum**

vabicaserin


(9*aR*^{*},12*aS*^{*})-4,5,6,7,9,9*a*,10,11,12,12*a*-decahydrocyclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinoline

vabicasérine

(-)-(9*aR*^{*},12*aS*^{*})-4,5,6,7,9,9*a*,10,11,12,12*a*-décahydrocyclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinoléine

vabicaserina

(-)-(9*aR*^{*},12*aS*^{*})-4,5,6,7,9,9*a*,10,11,12,12*a*-decahidrociclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinolina

$C_{15}H_{20}N_2$ 

or enantiomer, (-)-isomer
ou énantiomère, (-)-isomère
o enantiómero, (-)-isómero

vaptadinum


vaptadine

5,6-dihydrospiro(imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine)-3-carboxamide

vaptadine

5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazépine-11,4'-pipéridine]-3-carboxamide

vaptadina

5,6-dihidrospiro(11*H*-imidazo[2,1-*b*][3]benzazepina-11,4'-piperidina)-3-carboxamida $C_{17}H_{20}N_4O$ **veliflaponum**


veliflapon

(2*R*)-cyclopentyl{4-[(quinolin-2-yl)methoxy]phenyl}acetic acid

véliflapon

(+) -acide (2*R*)-cyclopentyl[4-(quinoléin-2-ylméthoxy)phényl]acétique

veliflapón

(+) -ácido (2*R*)-ciclopentil[4-(quinolin-2-ilmetoxi)fenil]acético $C_{23}H_{23}NO_3$ **volinanserinum**

volinanserin


(R)-(2,3-dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}=methanol

volinansérine

(+)-(*R*)-(2,3-diméthoxyphényl)[1-[2-(4-fluorophényl)éthyl]pipéridin-4-yl]méthanol

volinanserina

(+)-(*R*)-(2,3-dimetoxifenil)[1-[2-(4-fluorofenil)etil]piperidin-4-il]metanol




**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Non Proprietary Names (Rec. INN): List 53
Dénominations communes internationales recommandées (DCI Rec.): Liste 53
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 53
(WHO Drug Information, Vol. 19, No. 1, 2005)

p. 80 *delete/supprimer/suprimase* *insert/insérer/insertése*
 gantacurium chloridum gantacurii chloridum

p. 88 **panitumumabun**
 panitumumab *replace the molecular formula by the following*
 panitumumab *remplacer la formule brute par la suivante*
 panitumumab *sustitúyase la fórmula molecular por la siguiente*



p. 88 **pelitinibum**
 pelitinib *sustitúyase el nombre químico por el siguiente:*
 (2E)-N-[3-ciano-4-[(3-cloro-4-fluorofenil)amino]-7-etoxiquinolin-6-il]-
 4-(dimetilamino)-2-butenamina

Recommended International Non Proprietary Names (Rec. INN): List 55
Dénominations communes internationales recommandées (DCI Rec.): Liste 55
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 55
(WHO Drug Information, Vol. 20, No. 1, 2006)

p. 45 *suprimáse* *insértese*
 nebicapone nebicapona

* Electronic structure available on Mednet: <http://mednet.who.int/>

* Structure électronique disponible sur Mednet: <http://mednet.who.int/>

* Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.